AMNEAL PHARMACEUTICALS, INC. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-06: Disclosure Non Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-06: Disclosure Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-06: Disclosure Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-06: Disclosure Non Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-06 10-Q | Non Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-08-06 10-Q | Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-08-06 10-Q | Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-06 10-Q | Non Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-05-07 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-07 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-07 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-07 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-03-25 DEF 14A | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-03-25 DEF 14A | Award Timing MNPI Disclosure | 2025-01-01..2025-12-31 | We do not currently grant new awards of stock options, stock appreciation rights or similar option-like equity awards. Accordingly, we have no specific policy or practice on the timing of grants of such awards in relation to the disclosure of material nonpublic information. In the event we determine… | |
| 2026-03-25 DEF 14A | Award Timing How MNPI Considered | 2025-01-01..2025-12-31 | Accordingly, we have no specific policy or practice on the timing of grants of such awards in relation to the disclosure of material nonpublic information. In the event we determine to grant new awards of stock options or similar equity awards in the future, the Compensation Committee will evaluate … | |
| 2026-03-25 DEF 14A | Award Timing MNPI Considered | 2025-01-01..2025-12-31 | No | |
| 2026-03-25 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2025-01-01..2025-12-31 | No | |
| 2026-03-25 DEF 14A | Pay versus Performance Table | 2025-01-01..2025-12-31 | Pay Versus Performance Disclosure In accordance with rules adopted by the Securities and Exchange Commission pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we provide the following disclosure regarding executive compensation for our principal executive officers (“… | |
| 2026-03-25 DEF 14A | PEO Total Compensation | Individual: ChiragPatel | 2025-01-01..2025-12-31 | $8.69M |
| 2026-03-25 DEF 14A | PEO Total Compensation | Individual: ChintuPatel | 2025-01-01..2025-12-31 | $8.73M |
| 2026-03-25 DEF 14A | PEO Actually Paid Compensation | Individual: ChiragPatel | 2025-01-01..2025-12-31 | $24.32M |
| 2026-03-25 DEF 14A | PEO Actually Paid Compensation | Individual: ChintuPatel | 2025-01-01..2025-12-31 | $24.36M |
| 2026-03-25 DEF 14A | PEO Total Compensation | Individual: ChiragPatel | 2024-01-01..2024-12-31 | $7.19M |
| 2026-03-25 DEF 14A | PEO Total Compensation | Individual: ChintuPatel | 2024-01-01..2024-12-31 | $7.19M |
| 2026-03-25 DEF 14A | PEO Actually Paid Compensation | Individual: ChiragPatel | 2024-01-01..2024-12-31 | $11.85M |
| 2026-03-25 DEF 14A | PEO Actually Paid Compensation | Individual: ChintuPatel | 2024-01-01..2024-12-31 | $11.85M |
| 2026-03-25 DEF 14A | PEO Total Compensation | Individual: ChiragPatel | 2023-01-01..2023-12-31 | $2.37M |
| 2026-03-25 DEF 14A | PEO Total Compensation | Individual: ChintuPatel | 2023-01-01..2023-12-31 | $2.37M |
| 2026-03-25 DEF 14A | PEO Actually Paid Compensation | Individual: ChiragPatel | 2023-01-01..2023-12-31 | $9.46M |
| 2026-03-25 DEF 14A | PEO Actually Paid Compensation | Individual: ChintuPatel | 2023-01-01..2023-12-31 | $9.46M |
| 2026-03-25 DEF 14A | PEO Total Compensation | Individual: ChiragPatel | 2022-01-01..2022-12-31 | $5.05M |
| 2026-03-25 DEF 14A | PEO Total Compensation | Individual: ChintuPatel | 2022-01-01..2022-12-31 | $5.06M |
| 2026-03-25 DEF 14A | PEO Actually Paid Compensation | Individual: ChiragPatel | 2022-01-01..2022-12-31 | -$1.84M |
| 2026-03-25 DEF 14A | PEO Actually Paid Compensation | Individual: ChintuPatel | 2022-01-01..2022-12-31 | -$1.82M |
| 2026-03-25 DEF 14A | PEO Total Compensation | Individual: ChiragPatel | 2021-01-01..2021-12-31 | $4.79M |
| 2026-03-25 DEF 14A | PEO Total Compensation | Individual: ChintuPatel | 2021-01-01..2021-12-31 | $4.80M |
| 2026-03-25 DEF 14A | PEO Actually Paid Compensation | Individual: ChiragPatel | 2021-01-01..2021-12-31 | $1.38M |
| 2026-03-25 DEF 14A | PEO Actually Paid Compensation | Individual: ChintuPatel | 2021-01-01..2021-12-31 | $1.40M |
| 2026-03-25 DEF 14A | Named Executive Officers Footnote | 2025-01-01..2025-12-31 | (1) Chirag Patel and Chintu Patel were our Co-PEOs for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below. 2021 2022-2025 Andrew Boyer Andrew Boyer Anastasios Konidaris Anastasios Konidaris Nikita Shah Nikita Shah Joseph Todisco Jason Daly | |
| 2026-03-25 DEF 14A | PEO Name | Individual: ChiragPatel | 2021-01-01..2021-12-31 | Chirag Patel |
| 2026-03-25 DEF 14A | PEO Name | Individual: ChiragPatel | 2022-01-01..2022-12-31 | Chirag Patel |
| 2026-03-25 DEF 14A | PEO Name | Individual: ChiragPatel | 2023-01-01..2023-12-31 | Chirag Patel |
| 2026-03-25 DEF 14A | PEO Name | Individual: ChiragPatel | 2024-01-01..2024-12-31 | Chirag Patel |
| 2026-03-25 DEF 14A | PEO Name | Individual: ChiragPatel | 2025-01-01..2025-12-31 | Chirag Patel |
| 2026-03-25 DEF 14A | PEO Name | Individual: ChintuPatel | 2021-01-01..2021-12-31 | Chintu Patel |
| 2026-03-25 DEF 14A | PEO Name | Individual: ChintuPatel | 2022-01-01..2022-12-31 | Chintu Patel |
| 2026-03-25 DEF 14A | PEO Name | Individual: ChintuPatel | 2023-01-01..2023-12-31 | Chintu Patel |
| 2026-03-25 DEF 14A | PEO Name | Individual: ChintuPatel | 2024-01-01..2024-12-31 | Chintu Patel |
| 2026-03-25 DEF 14A | PEO Name | Individual: ChintuPatel | 2025-01-01..2025-12-31 | Chintu Patel |
| 2026-03-25 DEF 14A | Additional402v Disclosure | 2025-01-01..2025-12-31 | The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as … | |
| 2026-03-25 DEF 14A | Adjustment To PEO Compensation Footnote | 2025-01-01..2025-12-31 | Year Summary Compensation Table Total for Chirag Patel ($) Exclusion of Stock Awards for Chirag Patel ($) Inclusion of Equity Values for Chirag Patel ($) Compensation Actually Paid to Chirag Patel ($) 2025 8,691,745 (6,974,995) 22,607,663 24,324,413 Year Summary Compensation Table Total for Chintu P… | |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo; Individual: ChiragPatel | 2025-01-01..2025-12-31 | -$6.97M |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTbl; ExecutiveCategory: Peo; Individual: ChiragPatel | 2025-01-01..2025-12-31 | $22.61M |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo; Individual: ChintuPatel | 2025-01-01..2025-12-31 | -$6.97M |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTbl; ExecutiveCategory: Peo; Individual: ChintuPatel | 2025-01-01..2025-12-31 | $22.61M |
| 2026-03-25 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2025-01-01..2025-12-31 | Year Average Summary Compensation Table Total for Non-PEO NEOs ($) Average Exclusion of Stock Awards and Option Awards for Non-PEO NEOs ($) Average Inclusion of Equity Values for Non-PEO NEOs ($) Average Compensation Actually Paid to Non-PEO NEOs ($) 2025 2,975,421 (1,982,881) 7,878,384 8,870,994 Ye… | |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$1.98M |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTbl; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $7.88M |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo; Individual: ChiragPatel | 2025-01-01..2025-12-31 | $10.59M |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo; Individual: ChiragPatel | 2025-01-01..2025-12-31 | $11.14M |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo; Individual: ChiragPatel | 2025-01-01..2025-12-31 | $0.00 |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo; Individual: ChiragPatel | 2025-01-01..2025-12-31 | $877.73K |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo; Individual: ChintuPatel | 2025-01-01..2025-12-31 | $10.59M |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo; Individual: ChintuPatel | 2025-01-01..2025-12-31 | $11.14M |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo; Individual: ChintuPatel | 2025-01-01..2025-12-31 | $0.00 |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo; Individual: ChintuPatel | 2025-01-01..2025-12-31 | $877.73K |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $2.98M |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $4.58M |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $319.83K |
| 2026-03-25 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $0.00 |
| 2026-03-25 DEF 14A | Peer Group Issuers Footnote | 2025-01-01..2025-12-31 | The Peer Group TSR set forth in this table utilizes the Dow Jones U.S. Select Pharmaceuticals Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K, included in our Annual Report for the year ended December 31, 2025. The comparison assumes $100 was inv… | |
| 2026-03-25 DEF 14A | Non Gaap Measure Description | Measure: 1 | 2025-01-01..2025-12-31 | We determined Adjusted EBITDA to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEOs and Non-PEO NEOs in 2025. We may determine a different financial performance measure to be the most important financial performance measure … |
| 2026-03-25 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2025-01-01..2025-12-31 | The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, and the Company’s cumulative TSR over the five most recently completed fiscal years and the Dow Jones U.S. Select Pharmaceuticals Index TSR. … | |
| 2026-03-25 DEF 14A | Total Shareholder Return Vs Peer Group | 2025-01-01..2025-12-31 | The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, and the Company’s cumulative TSR over the five most recently completed fiscal years and the Dow Jones U.S. Select Pharmaceuticals Index TSR. … | |
| 2026-03-25 DEF 14A | Compensation Actually Paid Vs Net Income | 2025-01-01..2025-12-31 | The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, and our net income during the five most recently completed fiscal years. PEO and Average Non-PEO NEO Compensation Actually Paid Versus Net In… | |
| 2026-03-25 DEF 14A | Compensation Actually Paid Vs Company Selected Measure | 2025-01-01..2025-12-31 | The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Adjusted EBITDA during the five most recently completed fiscal years. PEO and Average Non-PEO NEO Compensation Actually Paid Versus Ad… | |
| 2026-03-25 DEF 14A | Tabular List Table | 2025-01-01..2025-12-31 | Tabular List of Most Important Financial Performance Measures The following table presents the financial performance measures that the Company considers to have been the most important in linking Compensation Actually Paid to our PEOs and other NEOs for 2024 to Company performance. The measures in t… | |
| 2026-02-27 10-K | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-02-27 10-K | Non Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-02-27 10-K | Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-02-27 10-K | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-02-27 10-K | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |